

The group's investment will facilitate the development of projects in the field of personalized medicine, and will strengthen its Diagnostic division

Grifols acquires 60% of the capital of Spanish biotechnology firm Progenika Biopharma

- **Progenika specializes in the design and manufacture of *in vitro* genome-based diagnostic tests, prognosis of diseases and prediction of responses to pharmacological treatment. It is also a leader in the development of DNA-based prognosis and diagnostic technologies.**
- **The total value of the operation is 37 million euros. Payment has been a combination of cash (50%) and non-voting (Class B) Grifols shares**

Barcelona, March 4, 2013: Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), the world's third largest plasma product manufacturer and a pioneer in the research and development of therapeutic alternatives designed to contribute to both scientific and social development, has acquired 60% of the equity of Spanish biotechnology firm Progenika Biopharma, for 37 million euros. The operation was performed through a combination of cash for 50% of the purchase price, with the remaining 50% being paid in the form of non-voting (Class B) Grifols shares.

Progenika specializes in the development of technology for personalized medicine, focusing on the design and manufacture of *in vitro* genome-based diagnostic tests, disease prognosis and prediction of responses to pharmacological treatment. It has also developed its own technology for the production of DNA chips for diagnosis and prognosis, and it is an international leader in this field. In particular, Progenika has pioneered the development of molecular biology tests for the performance of transfusional compatibility studies.

With this acquisition, Grifols strengthens the viability of existing Progenika projects, and reinforces its commitment to research and development within its Diagnostic division, by incorporating cutting-edge technology into its immunohematology product portfolio. Since 2010, Grifols has held the global distribution rights (excluding Mexico) for Progenika's blood genotyping test, BLOODchip®, facilitating the availability of donor–recipient compatible blood units, and increasing transfusional safety.

Progenika currently has a reference laboratory in Boston (Massachusetts, United States) specializing in blood genotyping using DNA techniques.

Grifols and the sellers have granted each other purchase and sale option rights over the shares representing the remaining company's equity, with a 3-year period for the exercise of these options. The price of the shares under the sale and purchase option will be the same as the price paid for the shares in the initial deal, increased by a 5% simple interest annual rate.

Finally, with the aim of preserving the identity of Progenika as a key element of the economic and business structure of the Basque Country, Grifols and Progenika have agreed that the investment vehicle EKARPEN SPE, S.A., owned by the Basque Government, Kutxabank, Caja Laboral –Euskadiko Kutxa, Lagun Aro and the Provincial Governments of the Basque Country, will continue to support Progenika and its new controlling shareholder in Progenika's new phase as a part of Grifols. Ekarpén will perform this role as a member of the Board of Directors of Progenika.

BBVA and law firm Osborne Clarke were advisors to the operation.

About Grifols

Grifols is a global healthcare company with a 70-year legacy of improving people's health and well being through the development of life-saving plasma medicines, hospital pharmacy products and diagnostic technology for clinical use.

As the third largest global producer of plasma medicines, Grifols has a presence in more than 100 countries and is the world leader in plasma collection, with 150 plasma donation centers across the U.S. Grifols is committed to increasing patient access to its life-saving plasma medicines through significant manufacturing expansions and the development of new therapeutic applications of plasma proteins. The company is headquartered in Barcelona, Spain and employs more than 11,000 people worldwide.

In 2012, Grifols' sales exceeded 2,620 million euros. The company's class A shares are listed on the Spanish Stock Exchange, where they form part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com

About Progenika

Progenika Biopharma SA is a biotechnology company specialised in personalized medicine that develops DNA biochips for the diagnosis, prognosis and prediction of response to treatment human diseases.

Progenika offers a series of tools for molecular diagnosis in areas such as: immunohematology, familial hypercholesterolemia, nervous system disorders, and

GRIFOLS

treatment optimization. In addition to BLOODchip, other leading products include LIPOchip, PHARMAchip, and Promonitor. Progenika was founded in 2000 and has development and production centres in Bizkaia Technology Park (Spain), Medford (Massachusetts, USA) and Mexico D.F. Its products are marketed in America, Europe and the Middle East.

DISCLAIMER

The facts and figures contained in this report which do not refer to historical data are “projections and forward-looking statements”. The words and expressions like “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “try to achieve”, “estimate”, “future” and similar expressions, insofar as they are related to Grifols Group, are used to identify projections and forward-looking statements. These expressions reflect the assumptions, hypothesis, expectations and anticipations of the management team at the date of preparation of this report, which are subject to a number of factors that could make the real results differ considerably. The future results of Grifols Group could be affected by events related to its own activity, such as shortages of raw materials for the manufacture of its products, the launch of competitive products or changes in the regulations of markets in which it operates, among others. At the date of preparation of this report Grifols Group has adopted the measures it considers necessary to offset the possible effects of these events. Grifols, S.A. does not assume any obligation to publicly inform, review or update any projections and forward-looking statements to adapt them to facts or circumstances following the preparation of this report, except as specifically required by law.

This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market Law 24/1988, of July 28, the Royal Decree-Law 5/2005, of March 11, and/or Royal Decree 1310/2005, of November 4, and its implementing regulations.